dihexa stack Capsules 10mg for Research Dihexa API | CAS 1401708-83-5

The REDEFINE clinical trial program has established that: Cagrilintide 2.4 mg + Semaglutide 2.4 mg weekly produces superior weight loss compared to either agent alone The combination achieved 22.7% mean weight reduction at 68 weeks Side effect profiles were manageable with proper dose escalation The amylin + GLP-1 agonist combination demonstrated synergistic effects This validated combination demonstrates that pairing cagrilintide with incretin-based therapies can work effectively

Genomics 49 (4), 287298

Dogra et al., 2024) (Figure 2B)

What is known: because unregulated injectable peptides may harbor contaminants, youre taking a chance on your health if you use one

Youre likely familiar with insulin (which helps regulate blood sugar) and oxytocin (often associated with social bonding)

Code Availability The reproducibility of the curation algorithm can be verified by executing the provided scripts on Code Ocean 25